spacer
home > epc > Summer 2015
PUBLICATIONS

European Pharmaceutical Contractor

epc
Summer 2015

   
Text
PDF
bullet
introduction
Editor’s Letter

Graham Hughes homes in on the theme of patient protection in this issue, and discusses the features that have a regional focus.
 
view
download pdf
bullet
Marketplace & Business
Sponsor Marketplace

Time Trial

Karyn Korieth and Annick Anderson at CenterWatch put forward their company's analysis to highlight the huge variablility in sponsors' drug timelines - and across certain therapeutic areas - while advising on how developers can get up to speed.

 
view
download pdf
Market Entry

The American Dream


AmeriStart's Jim Worrell outlines how to go about breaking into the US market. He believes willing investment, innovation, patience and well-thought out decisions are crucial to seizing the opportunities on offer.

 
view
download pdf
Strategic Partnerships

Balancing Act


Graham Wylie at the Medical Research Network argues that true strategic partnerships rarely exist. As industry mindsets and outsourcing models alter, balancing the risks and rewards of a collaboration are key to its success.
 
view
download pdf
bullet
Legal & Regulatory
Vulnerable Populations

Patient Protection

Investigators' main priority should be ensuring the safety of patients, especially those in vulnerable populations. Theorem Clinical Research's Marc Hoffman summarises the stringent measures required to guard those who are most at risk.


 
 
view
download pdf
European Regulation

Within REACH


The deadline for compliance may be over two years away, but meeting REACH's chemicals standards is a resource-heavy task. So much so, in fact, that Jeannette Paulussen at WIL Research advocates enlisting external support to alleviate the burden.

 
view
download pdf
Anti-Bribery and Corruption

Prevention is Better Than Cure

If adequate defences are not implemented to prevent bribery, a company can be charged despite having no prior knowledge of an offence. Therefore, as Catriona Munro of Maclay Murray & Spens LLP underlines, pharma must be seen to be doing everything it can to avert such incidents.
 
view
download pdf
Intellectual Property

Expiry Date


Pharmaceutical marketing increasingly requires a long-term proposal, as Tina Rees-Pedlar at Marks & Clerk points out. With a solid plan in place, businesses can gain revenue from their products long past the patent expiry date.
 
view
download pdf
bullet
Clinical Development
505(b)(2) Pathway

Beyond the Cliff

Ken Phelps at Camargo Pharmaceutical Services offers a solution to the pharma cliff in the form of the FDA’s 505(b)(2) pathway. As the amount of drugs going off-patent diminishes, this route to approval can help generic companies boost revenue.





 
view
download pdf
Causality Assessments

Facing Adversity


Usually identified using the WHO's criteria, adverse drug reactions - and their causal relationships with products - are vital in preventing potential harm to study participants. But there are more reliable assessment methods available, claim Maxim Kosov, John Riefler and Maxim Belotserkovskiy of PSI CRO.

 
view
download pdf
bullet
IT Solutions
Information Management

Single Source

Storing information across multiple systems often results in time-consuming and error-prone clinical processes. Devising a single source of content adds visibility and control, which translates into faster therapy development, reasons Rik van Mol of Veeva Systems.
 
view
download pdf
bullet
Therapeutics
Variant Creutzfelt-Jakob Disease

Potential Prognosis

The number of people carrying variant Creutzfelt-Jakob disease is potentially huge – however, due to a lack of diagnostic tools, the total is unknown. EPC Industry Advisor Shelley Bowers sheds light on the ethical issues that may inhibit testing, even if more appropriate methods are found.
 
view
download pdf
bullet
Manufacturing Environment
Cytotoxic Injectables

Contract Capacity


Unless it currently exists or is already planned for, the capacity for the contract manufacture of cytotoxic injectables is likely to remain at a standstill. Jim Miller and Saul Richmond of PharmSource take us through the many barriers restricting progress in this area.
 
view
download pdf
bullet
Regional Focus
Clinical Research: Turkey

Land of Opportunity


At the centre of an emerging region, Turkey boasts a supportive regulatory framework, a large number of sites and diverse patients, and a competive cost structure. Ömer Sadun Okyaltırık and Yamin Khan of Pharm-Olam report.

 
view
download pdf

Interview
Q&A: Vaccines

Immune Response


Drawing on her 30 years spent in the research arena, Cynthia Dukes at ICON assesses the future of vaccines and the technologies used in their development.
 
view
download pdf
Industry Interview

Comply and Demand

Synergy Research Group’s Igor Stefanov and Yuri Afonchikov talk to EPC about standing out in the CRO crowd and their experience of Good Clinical Practice failings.
 
view
download pdf
bullet
Outsourcing
Outsourcing and Insurance

Risk and Reward

As global outsourcing continues to expand, Marsh’s Simon Thompson recommends that insurers capitalise on new gaps in the life sciences market, created by the evolving threats this trend brings.
 
view
download pdf
bullet
Mobile Devices
mHealth

Mobile Future


MEDL Mobile’s Dave Swartz questions why some pharma firms are still hesitant to utilise mobile technology. Its immense benefits are evident, he claims, emphasising that this is only the beginning of the journey.
 
view
download pdf
bullet
In Conclusion
In Conclusion

The Path to Prevention


Can finding a cure have the opposite of the desired effect? Graham Hughes explores the landscape of contagious and deadly diseases.
 
view
download pdf
   
spacer



Published quarterly in
February, May,
August and November

News and Press Releases

Avacta and Leeds University awarded £3.8m Medical Research Council funding to develop new diagnostic tests


More info >>

White Papers

Convergence in the Pharmaceutical Market

PCI Pharma Services

Convergence is currently playing a large part in the growth of the pharmaceutical market. The need for convergence is due to many factors including the declining economy and high competition within the sector. There are many convergences within this sector to date; these include the convergence of food based products with medical and health products and the convergence of prescription drugs to over the counter (OTC) products. Although convergence is helping the pharmaceutical industry expand and develop, it also poses some challenges; these include the regulatory outlook and counterfeiting.
More info >>

Industry Events

6th Annual Cancer Vaccines Conference

27-28 September 2017, Copthorne Tara Hotel, London UK

Cancer Vaccines 2017: Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies. SMi Group is thrilled to present the 6th annual Cancer Vaccines conference, taking place on 27th & 28th September 2017 in Central London, UK. Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement